Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakeshaft

Showing results (311-320 of 328) with videos related to

Pageof 33
Sort By:
JAMA|July 6, 2021
Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical TrialRyan J Courtney, Hayden McRobbie, Piotr Tutka, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
Annals of Clinical and Translational Neurology|December 2, 2020
Trait impulsivity in Juvenile Myoclonic EpilepsyAmy Shakeshaft, Naim Panjwani, Robert McDowall, et al.
Scientific Reports|February 22, 2022
Sex-specific disease modifiers in juvenile myoclonic epilepsyAmy Shakeshaft, Naim Panjwani, Amber Collingwood, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 29, 2023
Universal evaluation of MLC models in treatment planning systems based on a common set of dynamic testsJordi Saez, Raquel Bar-Deroma, Evelien Bogaert, et al.
Pageof 33

Showing results (311-320 of 328) with videos related to

Sort By:
Pageof 33
JAMA|July 6, 2021
Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical TrialRyan J Courtney, Hayden McRobbie, Piotr Tutka, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
Annals of Clinical and Translational Neurology|December 2, 2020
Trait impulsivity in Juvenile Myoclonic EpilepsyAmy Shakeshaft, Naim Panjwani, Robert McDowall, et al.
Scientific Reports|February 22, 2022
Sex-specific disease modifiers in juvenile myoclonic epilepsyAmy Shakeshaft, Naim Panjwani, Amber Collingwood, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 29, 2023
Universal evaluation of MLC models in treatment planning systems based on a common set of dynamic testsJordi Saez, Raquel Bar-Deroma, Evelien Bogaert, et al.
Pageof 33